Cargando…

Mutations and thrombosis in essential thrombocythemia

Detalles Bibliográficos
Autores principales:	Guglielmelli, Paola, Gangat, Naseema, Coltro, Giacomo, Lasho, Terra L., Loscocco, Giuseppe Gaetano, Finke, Christy M., Morsia, Erika, Sordi, Benedetta, Szuber, Natasha, Hanson, Curtis A., Pardanani, Animesh, Vannucchi, Alessandro M., Tefferi, Ayalew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079671/ https://www.ncbi.nlm.nih.gov/pubmed/33907189 http://dx.doi.org/10.1038/s41408-021-00470-y

Ejemplares similares

MPL-mutated essential thrombocythemia: a morphologic reappraisal
por: Szuber, Natasha, et al.
Publicado: (2018)

Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates
por: Szuber, Natasha, et al.
Publicado: (2018)

Site‐specific venous thrombosis in essential thrombocythemia: Impact on subsequent vascular events and survival
por: Gangat, Naseema, et al.
Publicado: (2022)

U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Genetic predictors of response to specific drugs in primary myelofibrosis
por: Penna, Domenico, et al.
Publicado: (2018)

Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases
por: Gangat, Naseema, et al.
Publicado: (2022)

CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival
por: Szuber, Natasha, et al.
Publicado: (2018)

JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views
por: Gangat, Naseema, et al.
Publicado: (2021)

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
por: Tefferi, Ayalew, et al.
Publicado: (2018)

A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy
por: Gangat, Naseema, et al.
Publicado: (2019)

1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events
por: Gangat, Naseema, et al.
Publicado: (2022)

Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients
por: Nicolosi, Maura, et al.
Publicado: (2018)

Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients
por: Loscocco, Giuseppe G., et al.
Publicado: (2021)

Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model
por: Vallapureddy, Rangit R., et al.
Publicado: (2019)

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
por: Tefferi, Ayalew, et al.
Publicado: (2023)

Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms
por: Patnaik, Mrinal M., et al.
Publicado: (2018)

Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q)
por: Tefferi, Ayalew, et al.
Publicado: (2017)

EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental
por: Patnaik, Mrinal M., et al.
Publicado: (2018)

Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis
por: Mudireddy, Mythri, et al.
Publicado: (2018)

World Health Organization class-independent risk categorization in mastocytosis
por: Pardanani, Animesh, et al.
Publicado: (2019)

Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape
por: Tefferi, Ayalew, et al.
Publicado: (2022)

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
por: Lasho, Terra L., et al.
Publicado: (2018)

Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?
por: Nicolosi, Maura, et al.
Publicado: (2018)

Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates
por: Shah, Sahrish, et al.
Publicado: (2017)

Myelofibrosis Treatment Algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes
por: Bezerra, Evandro D., et al.
Publicado: (2021)

Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients
por: Cerquozzi, S., et al.
Publicado: (2017)

Momelotinib therapy for myelofibrosis: a 7-year follow-up
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach
por: Carobbio, Alessandra, et al.
Publicado: (2023)

Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts
por: Mangaonkar, Abhishek A., et al.
Publicado: (2018)

Essential thrombocythemia treatment algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
por: Guglielmelli, Paola, et al.
Publicado: (2023)

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
por: Gangat, Naseema, et al.
Publicado: (2023)

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera
por: Guglielmelli, Paola, et al.
Publicado: (2022)

Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
por: Tefferi, A, et al.
Publicado: (2017)

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
por: Tefferi, A, et al.
Publicado: (2010)

Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points
por: Gangat, Naseema, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_el8ggobocmndd3taph8ugdg6rt